Abera Bioscience AB (FRA:8WK)

Abera Bioscience AB Balance Sheet

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	23.18	6.09	3.32	15.43	11.95	0.9
Cash & Short-Term Investments	23.18	6.09	3.32	15.43	11.95	0.9
Cash Growth	646.41%	83.49%	-78.50%	29.13%	1224.40%	-65.97%
Other Receivables	1.78	0.65	0.77	0.77	0.3	0.18
Receivables	1.78	0.65	0.77	0.77	0.3	0.18
Prepaid Expenses	4.74	3.91	3.38	1.49	0.19	-
Other Current Assets	-	-	-	-0	-	-
Total Current Assets	29.69	10.65	7.46	17.69	12.44	1.08
Property, Plant & Equipment	1.29	1.07	-	-	-	-
Long-Term Deferred Charges	1.89	1.89	1.89	1.89	1.89	1.89
Other Long-Term Assets	1.2	-0	-	-	17.05	-
Total Assets	34.07	13.6	9.35	19.57	31.37	2.97
Accounts Payable	4.88	1.23	2.2	1.67	0.99	0.13
Accrued Expenses	0.64	0.95	1.23	0.97	1.17	1.36
Other Current Liabilities	0.47	2.77	0.27	0.16	0.07	1.05
Total Current Liabilities	5.99	4.95	3.69	2.8	2.22	2.54
Other Long-Term Liabilities	-	-	-	-0	-0	-
Total Liabilities	5.99	4.95	3.69	2.8	2.22	2.54
Common Stock	1.46	1.23	1.16	1.03	0.84	0.56
Additional Paid-In Capital	89.73	68.89	64.86	59.39	52.49	14.97
Retained Earnings	-63.12	-61.46	-60.36	-44.11	-24.73	-15.56
Comprehensive Income & Other	-	-	0	0.47	0.56	0.47
Shareholders' Equity	28.08	8.66	5.66	16.78	29.15	0.43
Total Liabilities & Equity	34.07	13.6	9.35	19.57	31.37	2.97
Net Cash (Debt)	23.18	6.09	3.32	15.43	11.95	0.9
Net Cash Growth	646.41%	83.49%	-78.50%	29.13%	1224.40%	-65.97%
Net Cash Per Share	-	0.39	0.25	1.32	1.17	0.13
Filing Date Shares Outstanding	-	15.35	14.46	12.91	11.57	10.46
Total Common Shares Outstanding	-	15.35	14.46	12.91	11.57	6.97
Working Capital	23.7	5.7	3.77	14.89	10.21	-1.46
Book Value Per Share	-	0.56	0.39	1.30	2.52	0.06
Tangible Book Value	28.08	8.66	5.66	16.78	29.15	0.43
Tangible Book Value Per Share	-	0.56	0.39	1.30	2.52	0.06

Source: S&P Global Market Intelligence. Standard template. Financial Sources.